Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVAT-122
- Development stage
- Unknown
- Lead developer
- Avata Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AVAT-122 (formerly SAP-022) is an aqueous solution formulation of synthetic cannabidiol (CBD) being developed by Avata Biosciences (formerly Sapient Therapeutics) for the treatment of pediatric focal epilepsy. Utilizing Avata's proprietary water-soluble cannabinoid formulation technology, AVAT-122 is designed to improve the bioavailability and delivery of cannabidiol without the use of oil, alcohol, or THC. Cannabidiol acts as a multi-target modulator, primarily targeting cannabinoid receptors 1 and 2 (CB1 and CB2), G-protein coupled receptor 55 (GPR55), and transient receptor potential vanilloid type 1 (TRPV1) channels to reduce neuronal hyperexcitability. AVAT-122 is currently in Phase 1 clinical development.
- Other names
- cannabidiol aqueous solutionsynthetic cannabidiol aqueous solution
02
Targets
CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)ENT1 (Solute carrier family 29 member 1)
Beyond the preview
Go deeper on AVAT-122.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVAT-122.